{"id":"W4319915130","doi":"10.1016/j.msard.2023.104561","title":"Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Medicine; Natalizumab; Dosing; Expanded Disability Status Scale; Physical therapy; Multiple sclerosis; Rating scale; Randomized controlled trial; Clinical trial; Internal medicine; Clinical endpoint; Progressive multifocal leukoencephalopathy; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00711917,0.002259831,0.004088446,0.0007527887,0.000657393,0.001628542,0.00139075,0.002652468,0.004788766],"category_scores_gemma":[0.008086303,0.0007541904,0.004961287,0.0005760841,0.001891562,0.002086014,0.000903851,0.004241551,0.0006272604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001042083,"about_ca_system_score_gemma":0.001484534,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006441259,"about_ca_topic_score_gemma":0.001193051,"domain_scores_codex":[0.992446,0.004885151,0.0006462968,0.0009722668,0.000610848,0.0004394648],"domain_scores_gemma":[0.9917675,0.002823158,0.002975386,0.0005122535,0.0005804405,0.001341124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9889472,0.003873673,0.0008141492,0.0003374139,0.001635627,0.00001479513,0.0000215057,0.0001391843,0.0005311801,0.0000505738,0.0001366267,0.003498021],"study_design_scores_gemma":[0.908967,0.08397222,0.004142543,0.00005696099,0.001474038,0.00002708785,0.00002137305,0.0005698613,0.000232369,0.0001679302,0.0003405199,0.00002827068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813572,0.005295804,0.001049625,0.0005070402,0.0007435675,0.007393221,0.001544713,0.00009416886,0.002014753],"genre_scores_gemma":[0.9814557,0.001276768,0.002645033,0.0008825858,0.000623019,0.01050601,0.00124667,0.00002191942,0.001342198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00711917,"threshold_uncertainty_score":0.03765017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08653767171726767,"score_gpt":0.302707932638336,"score_spread":0.2161702609210683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}